The Role of Dexmedetomidine As Myocardial Protection In Pediatric Cyanotic Congenital Heart Disease Undergoing Open Cardiac Surgery Using Cardiopulmonary Bypass Machine: A Preliminary Study

Model scores of the 29,894 trials active now.

Model score 14% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (273 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-07-16. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: myocardialheartinjurysurgerypatient
  Phrases that lowered it: openagedchildrencardiovascularcross
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Responsible party: principal investigator (lowers risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 16.5% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 4 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 0.08 (lowers risk) · Who can join
• Drug's FAERS reports marked serious: 93.5% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 3622 (raises risk) · Drug's FDA history
• Maximum age: 6 (raises risk) · Who can join
• Phase: 2/3 (raises risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot NCT05579964 · started 2022 · scored riskier than 37% of active trials completed
• Cardioprotective Effect of Ketamine-dexmeditomidine Versus Fentanyl-midazolam in Open Heart Surgery in Pediatrics NCT05314569 · started 2022 · scored riskier than 25% of active trials completed
• Use of Dexmedetomidine in Children Undergoing Cardiac Surgery NCT02375243 · started 2014 · scored riskier than 30% of active trials completed
• Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation NCT02519335 · started 2014 · scored riskier than 85% of active trials terminated
• Myocardial Protection With Adenosine Preconditioning NCT00881686 · started 2008 · scored riskier than 21% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.